Literature DB >> 1350789

c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.

D A Hilton1, K P West.   

Abstract

The prognostic value of c-erbB-2 protein expression was assessed retrospectively in 87 "curative" gastrectomy specimens from patients with gastric carcinoma. Tumours were stained immunohistochemically with the specific antibody 21N. Eight (9%) cases had strong membrane staining, all of which were of the intestinal type, and lymph node metastases, which showed concordance of staining in seven cases. In contrast to studies in breast cancer, positive cases showed a trend towards better five year survival, but this did not reach significance.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1350789      PMCID： PMC495317          DOI： 10.1136/jcp.45.5.454

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  9 in total

1.  An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.

Authors:  R A Walker; P V Senior; J L Jones; D R Critchley; J M Varley
Journal:  J Pathol       Date:  1989-06       Impact factor: 7.996

2.  Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.

Authors:  J B Park; J S Rhim; S C Park; S W Kimm; M H Kraus
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

3.  c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study.

Authors:  V G Falck; W J Gullick
Journal:  J Pathol       Date:  1989-10       Impact factor: 7.996

4.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

5.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.

Authors:  M Tal; M Wetzler; Z Josefberg; A Deutch; M Gutman; D Assaf; R Kris; Y Shiloh; D Givol; J Schlessinger
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

6.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

Authors:  Y Yonemura; I Ninomiya; A Yamaguchi; S Fushida; H Kimura; S Ohoyama; I Miyazaki; Y Endou; M Tanaka; T Sasaki
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

7.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

8.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

9.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.

Authors:  J Yokota; T Yamamoto; N Miyajima; K Toyoshima; N Nomura; H Sakamoto; T Yoshida; M Terada; T Sugimura
Journal:  Oncogene       Date:  1988-03       Impact factor: 9.867
  9 in total
  8 in total

1.  Prognostic significance of HER2/neu expression in gastric cancer.

Authors:  Julian Ananiev; Maya Gulubova; Irena Manolova; Georgi Tchernev
Journal:  Wien Klin Wochenschr       Date:  2011-07-11       Impact factor: 1.704

2.  NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

Authors:  A E Sirica; S Radaeva; N Caran
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  HER-2/neu amplification is an independent prognostic factor in gastric cancer.

Authors:  Dong Il Park; Jung Won Yun; Jung Ho Park; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Chang Hak Yoo; Byung Ho Son; Eun Yoon Cho; Seoung Wan Chae; Eo-Jin Kim; Jin Hee Sohn; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

4.  p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis.

Authors:  Stefan Kubicka; Christiane Claas; Sven Staab; Florian Kühnel; Lars Zender; Christian Trautwein; Siegfried Wagner; Karl Lenhard Rudolph; Michael Manns
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro.

Authors:  J J Bernstein; W J Goldberg; E R Laws
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Authors:  M A Gordon; H M Gundacker; J Benedetti; J S Macdonald; J C Baranda; W J Levin; C D Blanke; W Elatre; P Weng; J Y Zhou; H J Lenz; M F Press
Journal:  Ann Oncol       Date:  2013-03-22       Impact factor: 32.976

7.  Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.

Authors:  J F Fléjou; F Paraf; F Muzeau; F Fékété; D Hénin; S Jothy; F Potet
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

8.  HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.

Authors:  Giuseppe Aprile; Giovanna De Maglio; Jessica Menis; Mariaelena Casagrande; Francesco Tuniz; Edith Federica Pisa; Caterina Fontanella; Miran Skrap; Alberto Carlo Beltrami; Gianpiero Fasola; Stefano Pizzolitto
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.